Actinium Pharmaceuticals Inc (ATNM) Stock Sees a-8.00 Decrease

The stock of Actinium Pharmaceuticals Inc (ATNM) has seen a -26.62% decrease in the past week, with a -18.76% drop in the past month, and a 33.40% flourish in the past quarter. The volatility ratio for the week is 9.49%, and the volatility levels for the past 30 days are at 8.26% for ATNM. The simple moving average for the past 20 days is -22.78% for ATNM’s stock, with a 6.79% simple moving average for the past 200 days.

Is It Worth Investing in Actinium Pharmaceuticals Inc (AMEX: ATNM) Right Now?

Additionally, the 36-month beta value for ATNM is 0.11. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The public float for ATNM is 28.26M and currently, short sellers hold a 7.74% ratio of that float. The average trading volume of ATNM on April 19, 2024 was 353.92K shares.

ATNM) stock’s latest price update

Actinium Pharmaceuticals Inc (AMEX: ATNM)’s stock price has dropped by -8.00 in relation to previous closing price of 7.25. Nevertheless, the company has seen a loss of -26.62% in its stock price over the last five trading days. InvestorPlace reported 2024-04-15 that The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result.

Analysts’ Opinion of ATNM

Many brokerage firms have already submitted their reports for ATNM stocks, with HSBC Securities repeating the rating for ATNM by listing it as a “Buy.” The predicted price for ATNM in the upcoming period, according to HSBC Securities is $11.60 based on the research report published on September 06, 2023 of the previous year 2023.

Cantor Fitzgerald gave a rating of “Overweight” to ATNM, setting the target price at $20 in the report published on September 08th of the previous year.

ATNM Trading at -11.87% from the 50-Day Moving Average

After a stumble in the market that brought ATNM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.35% of loss for the given period.

Volatility was left at 8.26%, however, over the last 30 days, the volatility rate increased by 9.49%, as shares sank -22.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.09% upper at present.

During the last 5 trading sessions, ATNM fell by -26.62%, which changed the moving average for the period of 200-days by -9.50% in comparison to the 20-day moving average, which settled at $8.54. In addition, Actinium Pharmaceuticals Inc saw 31.30% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for ATNM

Current profitability levels for the company are sitting at:

  • -640.99 for the present operating margin
  • -8.75 for the gross margin

The net margin for Actinium Pharmaceuticals Inc stands at -595.94. The total capital return value is set at -0.71. Equity return is now at value -94.92, with -49.91 for asset returns.

Based on Actinium Pharmaceuticals Inc (ATNM), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -22.4. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is 94.92.

Currently, EBITDA for the company is -51.13 million with net debt to EBITDA at 1.46. When we switch over and look at the enterprise to sales, we see a ratio of 1500.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.21.


In conclusion, Actinium Pharmaceuticals Inc (ATNM) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts